Aegerion Pharmaceuticals Appoints Mark Fitzpatrick as CFO
Aegerion Pharmaceuticals, an emerging biopharmaceutical company, has appointed Mark Fitzpatrick as chief financial officer (CFO). He brings over 15 years of financial management experience in both public and private companies.
Most recently Fitzpatrick was vice president, CFO and assistant secretary at Proteon Therapeutics. Prior to this, he was vice president and CFO, treasurer and assistant secretary with RenaMed Biologics. He also held CFO positions with Dynogen Pharmaceuticals, WorldStreet Corporation and Diacrin. He previously was a senior auditor with Arthur Andersen & Co.